Table 4.
Multivariate survival analysis
| Parameter | Disease-specific survival | Local recurrence-free survival | Metastasis-free survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Tumor regression grade | 2.217 | 1.066-4.608 | 0.033* | 2.933 | 1.316-6.536 | 0.009* | 1.484 | 1.060-2.075 | 0.021* |
| SERPINB5 expression | 2.792 | 1.105-7.058 | 0.030* | 0.996 | 0.408-2.435 | 0.994 | 5.413 | 1.848-15.854 | 0.002* |
| Lymphovascular invasion | 2.671 | 1.004-7.108 | 0.049* | 4.097 | 1.337-12.551 | 0.014* | - | - | - |
| Pre-CCRT CEA | 2.180 | 1.025-4.639 | 0.043* | 2.653 | 1.090-6.028 | 0.031* | |||
| Post-CCRT T stage | 1.963 | 0.814-4.734 | 0.133 | 1.635 | 0.650-4.109 | 0.296 | 1.700 | 0.747-3.873 | 0.206 |
| Pre-CCRT N stage | - | - | - | 1.581 | 0.653-3.827 | 0.310 | - | - | - |